Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc.

OOTC:RTSL
0.00
USD
+0.00
(-66.67%)
0.01EPS
8.55P/E
565,264.06Market Cap

Total Valuation

USD

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. carries a market capitalization of 565,264.06, placing it among publicly traded companies globally. Its enterprise value stands at 4.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap565,264.06
Enterprise Value4.35M

Share Statistics

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. has 8.83M shares outstanding.

Shares Outstanding8.83M

Valuation Ratios

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. trades at a trailing price-to-earnings ratio of 8.55.

PE Ratio8.55
PB Ratio-0.21
P/TBV Ratio-0.19
P/FCF Ratio-2.03
P/OCF Ratio-0.90

Enterprise Valuation

These figures are as of June 30, 2023. Rapid Therapeutic Science Laboratories, Inc. trades at an EV/FCF ratio of 12.88, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.35M versus a market cap of 565,264.06, with the gap driven by net debt and cash on the balance sheet.

EV / FCF12.88

Financial Position

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. maintains a current ratio of 0.07, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -138.21, indicating conservative leverage, while an interest coverage ratio of -0.89 demonstrates limited ability to service its debt obligations.

Current Ratio0.07
Quick Ratio0.02
Debt / Equity-138.21
Debt / EBITDA-7.23
Interest Coverage-0.89

Financial Efficiency

These figures cover the twelve months ended June 30, 2023. Return on invested capital (ROIC) is negative at -67.21, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 2.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 79.55, useful for judging operating efficiency across full business cycles. The company generates approximately - - in revenue per employee across its workforce of 4.25, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)2.64
Return on Invested Capital (ROIC)-67.21
Return on Capital Employed (ROCE)79.55
Employee Count4.25

Stock Price Statistics

USD

As of the close on November 13, 2026, Rapid Therapeutic Science Laboratories, Inc.'s stock has declined approximately 93.33% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.14.

52-Week Price Change-93.33%
200-Day Moving Average0.14

Income Statement

USD

Over the twelve months ended June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. generated - - in revenue and converted that into 59,556.00 in net income, yielding earnings per share of 0.01. EBITDA reached -523,619.00, while operating income came in at -547,591.00.

Operating Income-547,591.00
Pretax Income59,556.00
Net Income59,556.00
EBITDA-523,619.00
EBIT-547,591.00
Earnings Per Share (EPS)0.01

Balance Sheet

USD

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. holds 2,160.00 in cash and equivalents against 3.79M in total debt, resulting in a net debt position of 3.45M. Total book value stands at -2.74M, with working capital of -4.11M providing operational flexibility.

Cash & Cash Equivalents2,160.00
Total Debt3.79M
Net Debt3.45M
Equity (Book Value)-2.74M
Book Value Per Share-0.31
Working Capital-4.11M

Cash Flow

USD

Rapid Therapeutic Science Laboratories, Inc. produced -566,601.00 in operating cash flow over the twelve months ended June 30, 2023. After subtracting 315,645.00 in capital expenditures, free cash flow totaled -250,956.00 - equivalent to -0.03 per share.

Operating Cash Flow-566,601.00
Capital Expenditures315,645.00
Free Cash Flow-250,956.00
FCF Per Share-0.03

Dividends & Yields

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -49.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.94, meaning Rapid Therapeutic Science Laboratories, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-24.94
FCF Yield-49.31

Stock Splits

Rapid Therapeutic Science Laboratories, Inc.'s most recent stock split took place on April 11, 2022 with a 25:1 split ratio.

Last Split Date4/11/2022
Split Ratio25:1

Scores

As of June 30, 2023, Rapid Therapeutic Science Laboratories, Inc. has an Altman Z-Score of -10.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-10.88